We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Peer-Reviewed Phase 3 Results of Baricitinib-Remdesivir Combo Published in NEJM
Peer-Reviewed Phase 3 Results of Baricitinib-Remdesivir Combo Published in NEJM
COVID-19 patients treated with Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) in combination with Gilead Sciences’ antiviral Veklury (remdesivir) were less likely to die after 28 days than those receiving remdesivir alone, according to peer-reviewed phase 3 trial results published online Friday in the New England Journal of Medicine.